Alzheimer disease (AD) is believed to have a long preclinical stage before apparent cognitive impairment. This stage may last for decades and is characterized by the presence of asymptomatic brain pathology, primarily β-amyloid (Aβ) accumulation. The accumulation can be detected by biomarkers in the form of decreased cerebrospinal fluid (CSF) levels of Aβ42 and increased uptake of Aβ ligands visualized by positron emission tomography (PET). The Aβ biomarkers are important for drug development since they enable trials to be conducted in people with Aβ accumulation in the symptomatic (tertiary prevention) or asymptomatic (secondary prevention) stage of the disease. In the absence of successful anti-Aβ trials, it remains unknown at what stage anti-Aβ treatment must be administered to be effective. One possibility is that the most effective approach would be to inhibit the initial accumulation of Aβ. If so, drug trials would need to be carried out in asymptomatic individuals who appear to lack amyloid accumulation but who are at high risk of developing it within a few years. Here we used longitudinal CSF Aβ42 to model the development of Aβ accumulation in cognitively healthy people. The indication of decline was defined as CSF Aβ42 crossing the threshold of 192 ng/L, which corresponds to Aβ positivity in imaging and autopsy studies. It is often assumed that Aβ biomarker changes occur before other biomarker changes in AD, but some studies have suggested that other brain changes (especially tau related) may precede Aβ...
accumulation. We therefore tested the hypothesis that baseline CSF Aβ42, biomarkers of neurodegeneration, demographic factors, and cognitive scores could be used to identify people at risk for Aβ accumulation as determined by low CSF Aβ42 levels, within 3 years.

Methods

Study Design
Data used in the preparation of this article were obtained from the Alzheimer Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the US Food and Drug Administration, private pharmaceutical companies, and non-profit organizations as a $60 million, 5-year, public-private partnership. The principal investigator of this initiative is Michael W. Weiner, MD, Veterans Affairs Medical Center and University of California, San Francisco. The ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations, and participants have been recruited from more than 50 sites across the United States and Canada. The initial goal of the ADNI was to recruit 800 individuals, but the ADNI has been followed by ADNI-Grand Opportunity (ADNI-GO) and ADNI-2. To date, these 3 protocols have enrolled more than 1500 adults aged 55 to 90 years to participate in the research, consisting of cognitively normal older individuals, people with early or late mild cognitive impairment, and people with early AD. The follow-up duration of each group is specified in the protocols for ADNI-1, ADNI-GO, and ADNI-2. Individuals originally recruited for ADNI-1 and ADNI-GO had the option to be monitored in ADNI-2.9 The present study was conducted from October 24, 2005, to September 1, 2014. Institutional review board approval was received at all involved sites. Written informed consent was obtained from all participants.

Cohort
Our study population consisted of cognitively healthy individuals serving as controls enrolled in ADNI-1 or ADNI-2. Inclusion and exclusion criteria have been described in detail.9 Briefly, all control participants included in ADNI were between the ages of 55 and 90 years, had completed at least 6 years of education, were fluent in Spanish or English, were free of any significant neurologic disease, had a Mini-Mental State Examination score of 24 or higher, and had a Clinical Dementia Rating scale score of 0. For the present study, we only included those with available longitudinal data on CSF Aβ42 levels and baseline CSF Aβ42 levels indicating a lack of Aβ accumulation at baseline as determined by a validated cutoff level (192 ng/L).

CSF Biomarkers
All participants underwent CSF sampling at baseline and at least once (yearly or every second year) in a follow-up visit during 3 years (or shorter in 5 individuals who became Aβ positive during follow-up). Measurement of levels of Aβ42, T-tau, and P-tau was performed using the multiplex xMAP Luminex platform (Luminex Corp) with the INNO-BIA AlzBio3 kit (Innogenetics) as described previously.5,12 Longitudinal samples for each participant were analyzed on the same plate in the same analytical run.13 Within-run coefficients of variation were 6.5% or less. Parts of the longitudinal data have been published.13

Cognition
The Alzheimer Disease Assessment Scale-Cognitive Subscale, version 11 (ADAS-cog11),14 logical memory delayed recall, Rey Auditory Verbal Learning Test (AVLT) delayed recall,15 and Trail Making Test, part B (Trail B)16 were performed at baseline. For analysis of longitudinal cognitive scores, we used up to 8 years of follow-up data.

Structural Magnetic Resonance Imaging
Brain scans using T1-weighted structural magnetic resonance imaging (MRI) were acquired at baseline with 1.5-T (ADNI-1) or 3-T (ADNI-2) MRI scanners using a sagittal volumetric magnetization-prepared rapid gradient echo nonacclerated sequence.17 Quantification was done in an automated pipeline using FreeSurfer (version 4.3 for ADNI-1 and version 5.1 for ADNI-2, http://surfer.nmr.mgh.harvard.edu/fswiki).18,19 Individuals whose quality control test results were below standard were excluded. Data on hippocampal volume (mean of right and left) were used. Hippocampal volume was adjusted for total intracranial volume. Because the acquisition and processing of images differed between ADNI-1 and ADNI-2, the data from these study groups were analyzed separately. Individuals with an adjusted hippocampal volume below the 25th percentile within each study group were labeled as having small hippocampal volume. The choice of the 25th percentile was a trade-off between achieving adequate group sizes and a level of hippocampal volume that may be associated with early-stage brain injury.

PET Imaging
We included data on ADNI-1 participants who had undergone carbon 11(11C)-labeled Pittsburgh compound B PET scanning and ADNI-2 participants who had undergone florbetapir F 18 PET scanning to test for the presence of brain Aβ accumulation as estimated by PET (using previously established cutoffs for 11C-Pittsburgh compound B, 1.47 standardized uptake volume ratio [SUVR],20 and 18F-florbetapir, 1.11 SUVR21-23).
Classification of CSF Aβ42 Decliners

We classified participants as CSF Aβ42 decliners if the observed CSF Aβ42 level became lower than 192 ng/L within 3 years. Those whose Aβ42 level remained negative at 3 years were classified as nondecliners. Ten individuals lacked data at exactly 3 years but had data available at 4 years, 5 years, or both. These participants were classified as nondecliners if the

Predicting CSF Aβ42 Decline

We performed random forest analyses with decliners vs nondecliners as the dependent variable and demographic factors, baseline biomarker data, and cognitive scores as predictors. The results are presented as OOB in the Table and as ROC curves for continuous predictors in Figure 2 (receiver operating characteristic curves are not meaningful for dichotomous predictors). Baseline CSF Aβ42 level was the strongest individual predictor of future decline (OOB accuracy, 79%; 95% CI, 70%-87%). The high diagnostic accuracy for baseline CSF Aβ42 was in agreement with the distribution of baseline CSF Aβ42 levels in decliners and nondecliners (Figure 1 and the Table). The individual decision trees for CSF Aβ42 favored splits at a level corresponding to the lower tertile of baseline CSF Aβ42 (225 ng/L). Among the 12 participants with baseline CSF Aβ42 levels less than 225 ng/L, 10 were decliners (positive predictive value, 83%). Among the 23 participants with baseline CSF Aβ42 levels of 225 ng/L or more, 22 were nondecliners (negative predictive value, 96%).

Baseline CSF P-tau levels also significantly predicted future decline (OOB accuracy, 68% [95% CI, 55%-81%]). The individual decision trees for CSF P-tau favored splits at CSF P-tau 25 ng/L, which was close to the upper tertile of baseline CSF P-tau (26 ng/L) and also close to a previously suggested cutoff for CSF P-tau to identify AD (23 ng/L, when analyzed at the same laboratory and with the same assays as in the ADNI study28). Among the 10 participants with baseline CSF P-tau levels higher than 25 ng/L, 6 were decliners (positive predictive value, 60%). Among the 25 individuals with baseline CSF P-tau levels less than 25 ng/L, 20 were nondecliners (negative predictive value, 80%).

Sex, APOE ε2, APOE ε4, and small hippocampal volume also appeared to be significant individual predictors (OOB accuracy, 64%-69%) (Table). However, closer inspection of these random forest models revealed that the models classified all but one participant as nondecliners, and their OOB accuracy therefore corresponds to the percentage of nondecliners in the examined population.

We performed additional random forest analyses testing a combination of CSF Aβ42 and P-tau, which had an OOB accuracy rate of 84% (95% CI, 72%-97%). We also tried combinations of CSF Aβ42, P-tau, and other predictors. The best accuracy was seen for a combination of CSF Aβ42, P-tau, and the
The main finding of this study was that it is possible to predict declining levels of CSF Aβ42 in cognitively healthy individuals monitored for 3 years. Declining CSF Aβ42 was defined as the CSF Aβ42 level falling below the a priori-defined threshold of 192 ng/L. Baseline CSF Aβ42 level was a strong predictor of declining CSF Aβ42. Individuals with CSF Aβ42 levels in the lower tertile of the reference range were very likely to become Aβ positive during follow-up. The 192 ng/L cutoff was initially derived from a sample of patients with autopsy-confirmed AD dementia vs nonautopsy-confirmed controls. Aβ threshold, and corresponding thresholds used for Aβ PET imaging, may be too stringent to detect very early pathology. The findings of our study suggest that a more liberal (higher) cutoff level could be explored in cognitively healthy controls.

Previous studies have described a large variability in CSF Aβ42 levels among healthy controls, even for individuals who have CSF Aβ42 levels above the normal cutoff value. Theoretically, this variability could be the result of a combination of factors, including differences in production and clearance of the Aβ peptide. Thus, CSF Aβ42 levels in the low normal range could be due to a physiologically low Aβ production rate, which may not be associated with further decline. However, our finding contradicts this hypothesis and suggests that a low normal CSF Aβ42 level is rarely a benign phenomenon since it is strongly associated with future decline. The finding agrees with previous results using Aβ PET, in which cognitively healthy people who became Aβ positive during follow-up had a higher baseline Aβ signal than people who remained Aβ negative.

The recent failures of anti-amyloid drug trials, such as the phase 3 trials of bapinezumab and solanezumab, have been blamed partly on the fact that some of the participants did not have Aβ accumulation. In addition, the disease may be too advanced in patients with dementia for optimal intervention via an anti-amyloid mechanism since downstream effects of amyloid accumulation, especially tau pathology, may become self-propagating at some point. This theory is

---

**Table. Characteristics of the Study Population**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (N = 35)</th>
<th>CSF Aβ42 Decliners (n = 11)</th>
<th>CSF Aβ42 Nondecliners (n = 24)</th>
<th>P Value</th>
<th>Out-of-Bag Accuracy (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>76.1 (6.0)</td>
<td>76.0 (5.8)</td>
<td>76.1 (6.2)</td>
<td>.96</td>
<td>0.45 (0.32-0.58)</td>
</tr>
<tr>
<td>Education, y</td>
<td>15.7 (3.0)</td>
<td>16.0 (2.6)</td>
<td>15.5 (3.3)</td>
<td>.86</td>
<td>0.56 (0.45-0.68)</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>17 (49)</td>
<td>4 (36)</td>
<td>13 (54)</td>
<td>.54</td>
<td>0.69 (0.65-0.72)</td>
</tr>
<tr>
<td>Female</td>
<td>18 (51)</td>
<td>7 (64)</td>
<td>11 (46)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE ε2, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>7 (20)</td>
<td>1 (9)</td>
<td>6 (25)</td>
<td>.52</td>
<td>0.64 (0.57-0.71)</td>
</tr>
<tr>
<td>Negative</td>
<td>28 (80)</td>
<td>10 (90)</td>
<td>18 (75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE ε4, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>4 (11)</td>
<td>2 (18)</td>
<td>2 (8)</td>
<td>.78</td>
<td>0.69 (0.65-0.72)</td>
</tr>
<tr>
<td>Negative</td>
<td>31 (89)</td>
<td>9 (82)</td>
<td>22 (92)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADAS-cog</td>
<td>5.0 (2.3)</td>
<td>5.6 (2.8)</td>
<td>4.7 (2.0)</td>
<td>.35</td>
<td>0.59 (0.44-0.73)</td>
</tr>
<tr>
<td>Trail B</td>
<td>79.6 (24.7)</td>
<td>87.3 (31.8)</td>
<td>76.1 (20.6)</td>
<td>.34</td>
<td>0.54 (0.40-0.68)</td>
</tr>
<tr>
<td>Logical memory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>delayed recall</td>
<td>12.8 (3.8)</td>
<td>12.8 (3.3)</td>
<td>12.8 (4.0)</td>
<td>.89</td>
<td>0.58 (0.36-0.80)</td>
</tr>
<tr>
<td>AVLT delayed recall</td>
<td>8.5 (3.0)</td>
<td>7.6 (2.9)</td>
<td>9.0 (2.9)</td>
<td>.11</td>
<td>0.56 (0.39-0.73)</td>
</tr>
<tr>
<td>Baseline biomarkers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF Aβ42, ng/L</td>
<td>242 (31)</td>
<td>211 (12)</td>
<td>257 (25)</td>
<td>&lt;.001</td>
<td>0.79 (0.70-0.87)</td>
</tr>
<tr>
<td>CSF T-tau, ng/L</td>
<td>63 (21)</td>
<td>71 (25)</td>
<td>59 (18)</td>
<td>.15</td>
<td>0.45 (0.35-0.55)</td>
</tr>
<tr>
<td>CSF P-tau, ng/L</td>
<td>23 (7.9)</td>
<td>25 (7.9)</td>
<td>21 (7.8)</td>
<td>.16</td>
<td>0.68 (0.55-0.81)</td>
</tr>
<tr>
<td>Small hippocampus, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>True</td>
<td>10 (29)</td>
<td>3 (27)</td>
<td>7 (29)</td>
<td>&gt; .99</td>
<td>0.68 (0.65-0.71)</td>
</tr>
<tr>
<td>False</td>
<td>24 (69)</td>
<td>8 (73)</td>
<td>16 (67)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** Aβ, β-amyloid; ADAS-cog, Alzheimer Disease Assessment Scale–Cognitive Subscale; AVLT, Auditory Verbal Learning Test; CSF, cerebrospinal fluid; Trail B, Trail Making Test, part B.

*P* values are for comparisons between emerging Aβ accumulation (decliners) and the nondecliners (Mann-Whitney tests and χ² tests).

Out-of-bag accuracies (ranging from 0 to 1, where 1 is perfect accuracy) are from random forest analyses. Seven APOE ε2-positive participants had 1 APOE ε2 and 1 APOE ε3 allele. Three APOE ε4-positive participants had 1 APOE ε4 and 1 APOE ε3 allele and one individual had 1 APOE ε2 allele. For sex, APOE, and small hippocampus, the out-of-bag accuracy appears to be significant, but closer inspection of these models showed that they classified all cases (or all but 1 case) as nondecliners, and these accuracies therefore represent the frequency of nondecliners in the population.

Information was missing on 1 participant.
supported by some of the autopsy data from the AN1792 trial,\textsuperscript{15} in which amyloid immunization may have removed amyloid plaques without affecting the course of the disease. Several new trials therefore use Aβ biomarkers to verify that participants have amyloid accumulation, both for tertiary and secondary prevention, and/or focus on patients with less severe clinical disease.\textsuperscript{34,35} These results suggest that an even earlier prevention—before Aβ biomarkers have reached the cutoff normally associated with widespread pathology—could also be an attractive approach since there are several problems associated with treatment when pathology is established. For example, successful prevention in people with established amyloid accumulation may be hampered by a large variability in the length of time that individuals have been exposed to the toxic effects of amyloid. Some people may become amyloid positive very recently and others may have had amyloid depositions for years, putting them at higher risk for imminent spread of tau pathology and cognitive impairment. However, the benefits of primary prevention must be weighed against possible risks, costs, and the availability of early screening and intervention.

There has been discussion about whether Aβ or neurodegeneration appears first during the course of AD.\textsuperscript{7,8,10} Although the present study was not specifically aimed at answering this question, our results suggest that signs of Aβ accumulation and signs of tau-related neurodegeneration may appear early in the disease process since a high baseline CSF P-tau level was also a significant predictor of future Aβ level decline. Complicating analyses of preclinical Aβ and neurodegeneration, brain Aβ may have very early effects on neurodegeneration, even before Aβ biomarkers become clearly positive.\textsuperscript{30} The ADNI investigators\textsuperscript{27} recently found that hippocampal atrophy rates started to accelerate at CSF Aβ42 levels of approximately 220 ng/L,\textsuperscript{37} which was about the same level of CSF Aβ42 that was associated with a high risk of declining CSF Aβ42 in the present study. Together, these findings suggest that the emergence of Aβ accumulation and neurodegeneration is coupled even early (from a clinical perspective) in the disease process. Of course, these conclusions are based on currently available biomarker tools. For example, CSF Aβ42 may lack sensitivity for the most toxic forms of brain amyloid.

This study has several limitations. The main limitation is the small sample size, especially of CSF Aβ42 decliners, which restricts our power to identify significant predictors. The results therefore need to be confirmed in larger studies. Furthermore, the participants had a mean age of 76 years, and primary prevention of Aβ accumulation should be explored in younger individuals given the long duration of preclinical amyloid accumulation.\textsuperscript{38,39} The study group included few APOE ε4 carriers since most elderly APOE ε4 carriers are CSF Aβ42 positive at baseline. Thus, our results may not be generalizable to APOE ε4 carriers. Another possible limitation is the inclusion of individuals who were close to the cutoff level at baseline, which may lead to a bias by those crossing the threshold on the basis of random variation. However, the decliners decreased by a mean (SD) of 14.2% (5.9%) in CSF Aβ42 levels from baseline to their last measurement, which clearly exceeded the intra-assay variability for CSF Aβ42 (coefficient of variation, \(\pm 6.5\%\)). In contrast, although some participants who were classified as nondecliners had negative slopes, the mean (SD) change in the nondecliner group was within the intra-assay variability (\(-5.3\% \pm 9.5\%\)). This argues against random variation having a major effect on the classification of the participants. The fact that individuals who were classified as decliners had both lower baseline values and steeper decline of CSF Aβ42 levels than did those who were classified as nondecliners supports the idea that CSF Aβ42 levels may have a sigmoidal trajectory, as previously suggested.\textsuperscript{40} Our definition of decliners did not include people whose CSF Aβ42 level decreased without reaching the cutoff value (192 ng/L) within 3 years. Although some of those individuals may be moving toward Aβ accumulation, excluding them from the decliner group reflects possible procedures in future trials aimed at preventing Aβ accumulation. We only analyzed hippocampal volume as a predictor of future CSF Aβ42 level decline, but future studies may also explore other structures, including the precuneus, entorhinal, lateral temporal, and lateral parietal cortices. Likewise, several other cognitive tests could be explored. Recently, a composite score for secondary prevention AD trials was presented (Alzheimer’s Disease Cooperative Study–Preclinical Alzheimer Cognitive Composite).\textsuperscript{41} However, the ADNI procedures allow only an approximation of this score, and the effects of baseline Aβ level on the score were very mild in ADNI controls\textsuperscript{42}; therefore, we did not include the score in the present study. Finally, we could not confirm Aβ accumulation with an independent technology. Few participants in this group underwent PET Aβ imaging, and there was no evidence of PET Aβ positivity in the CSF Aβ42 decliners. This is difficult to interpret given the small number of people with PET imaging results available, but previous reports\textsuperscript{42,43} have suggested that CSF Aβ42 levels may be reduced before PET Aβ posi-
Predicting Reduction of CSF β-Amyloid 42

Conclusions

Our study shows that it is possible to identify individuals at risk for Aβ accumulation. Such people are primarily characterized by CSF Aβ42 levels slightly above the cutoff level of 192 ng/L. This finding is in agreement with a previously proposed model of sigmoidal Aβ biomarker trajectories, as well as with findings using Aβ PET, and adds to a previous determination that CSF proteins may be used to predict longitudinal reduction of CSF Aβ42. Individuals with CSF Aβ42 levels in the low reference range may be optimal candidates for early intervention trials aimed at thwarting further Aβ accumulation.

ARTICLE INFORMATION

Accepted for Publication: December 12, 2014.
Published Online: March 16, 2015.

Author Affiliations: Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden (Mattsson); Department of Radiology and Biomedical Imaging, University of California, San Francisco (Mattsson, Insel, Weiner); Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, California (Mattsson, Insel, Weiner); Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla (Donohue); Helen Wills Neuroscience Institute and School of Public Health, University of California, Berkeley (Jagust); Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Sperling); Alzheimer’s Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla (Aisen).

Author Contributions: Dr Mattsson had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Mattsson, Insel.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Mattsson, Insel.

Critical revision of the manuscript for important intellectual content: Donohue, Jagust, Sperling, Aisen, Weiner.

Statistical analysis: Mattsson, Insel.

Obtained funding: Mattsson, Jagust, Weiner.

Study supervision: Jagust, Weiner.

Conflict of Interest Disclosures: Dr Sperling has served as a consultant to Boehringer-Ingelheim, Eisai, Genentech, Isis, Janssen, Lundbeck, Merck, and Roche and has received research support from the Alzheimer’s Association, Eli Lilly and Company, Janssen, and the National Institute on Aging. Dr Jagust serves as a consultant to Genentech and Synarc Inc. Dr Weiner has been on scientific advisory boards for BOLT International and Pfizer; has been a consultant for the Alzheimer’s Drug Discovery Foundation, Easton Associates, Harvard University, mThought Research, Janssen, KLI Associates, Pfizer Inc, Sanofi-Aventis Groupe, and the University of California, Los Angeles; has received funding for travel from Alzheimer’s and Parkinson’s Diseases Congress, Danone Trading BV, MCI Group, France, Neuroscience School of Advanced Studies, Novartis, Paul Sabatier University, Pfizer, Tohoku University, Travel eDreams Inc, and Clinical Trials on Alzheimer’s Disease conference; serves as an associate editor of Alzheimer’s & Dementia; has received honoraria from Danone Trading BV, Pfizer, and Tohoku University; has received research support from Avid, Merck, the US Department of Defense, and the Veterans Administration; and has stock options in Elan and Synarc. No other conflicts were reported.

Funding/Support: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) through grant U01 AG024904 from the National Institutes of Health [NIH] and award W81XWH-12-2-0012 from the US Department of Defense. The ADNI is funded by the National Institute of Biomedical Imaging and Bioengineering, the National Institute on Aging, and through generous contributions from the Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Aracron Biotech, BioClinica Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Eisai Inc, Elan Pharmaceuticals Inc, Eli Lilly and Company, Euroimmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc, Fujirebio, GE Healthcare, IXICO Ltd, Janssen Alzheimer Immunotherapy Research & Development LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace Inc, Merck & Co Inc, Medscor, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc, Piramal Imaging, Servier, Synarc Inc, and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California. This research was also supported by grants P30 AG10129 and K01 AG030514 from the NIH, Carl-Bertil-Laurellsfond, Goteborgs Lakaresalfskap, Klinik Norden, Sahlgrenska Universitetssjukhuset, Svenska Lakaresalskapet, and the Swedish Research Council.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: A complete listing of the ADNI investigators can be found in the eAppendix in the Supplement.

REFERENCES


